Company Overview - Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for medically supervised settings [4] - The company's lead product candidate, Niyad™, is a lyophilized formulation of nafamostat, currently studied as an anticoagulant for the extracorporeal circuit and has received Breakthrough Device Designation from the FDA [4] - Talphera is also developing two pre-filled syringes in partnership with Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe [4] Financial Results Announcement - Talphera will release its third quarter 2024 financial results after market close on November 13, 2024 [1] - A live webcast and conference call will be held at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard Time to discuss the results and provide a business update [1] Webcast and Conference Call Details - The webcast can be accessed through the Investors section of Talphera's website, and a replay will be available for 90 days following the event [2] - Investors can participate in the conference call by dialing 1-800-836-8184 for North American callers or 1-646-357-8785 for international callers, with a conference ID of 89949 [3]

Company Overview - Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for use in medically supervised settings [2] - The company's lead product candidate, Niyad™, is a lyophilized formulation of nafamostat, currently studied as an anticoagulant for the extracorporeal circuit [2] - Niyad™ has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) [2] Upcoming Events - Talphera management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, scheduled for October 15-17, 2024 [1] - The specific session for Talphera is set for October 16, 2024, at 3:00 PM ET / 12:00 Noon PT [2] - Registered investors will have the opportunity for 1x1 meetings with Talphera management during the summit [1]

The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients completing the study after 72 hours Dr. Stuart Goldstein, a world-renowned nephrologist, is the first physician to enroll a patient in the NEPHRO CRRT study SAN MATEO, Calif., Aug. 19, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutic ...

Talphera, Inc. (NASDAQ:TLPH) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Founder and Chief Medical Officer Conference Call Participants Ed Arce - H.C. Wainwright Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Welcome to Talphera’s Second Quarter 2024 Financial Results Conference Call. This call is being webcasted live via the events page of the Invest ...

Exhibit 99.1 Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and ef ectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June 30, 2024 of $14.0 million Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET SAN MATEO, Calif., August 14, 2024 – Talphera, Inc. (Nas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 TALPHERA, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdiction of incorporati ...

NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June 30, 2024 of $14.0 million Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development ...

Talphera, Inc. (NASDAQ:TLPH) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Founder and Chief Medical Officer Conference Call Participants Ed Arce - H.C. Wainwright James Molloy - Alliance Global Partners Operator Welcome to the Talphera First Quarter 2024 Financial Results Conference Call. This call is being webcasted live via the Events page of the Investors section of Talphera's w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 TALPHERA, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdiction of incorporat ...

Exhibit 99.1 Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024 Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joins Talphera as Chief Development Of icer Cash and investments at March 31, 2024 of $18.6 million Conference call and webcast to be held Tuesday, May 14, 2024 at 4:30 pm ET SAN MATEO, Calif., May 14, 2024 – Talphera, Inc. ...